Novel Study on N-Nitrosamines as Risk Factors of Cardiovascular Diseases

Table 1

Changes in levels of total cholesterol, LDL, HDL, homocysteine and activities of lactate dehydrogenase and creatine kinase MB after treatment of male rats with a daily dose of dibuty-, ethylbutyl-, butylpropyl-, diethyl-, dimethyl- and diphenylnitrosamine for two weeks.

	Control	NDBA	NEBA	NBPA	NDEA	NDMA	NDPA
Total cholesterol; mg/dL	97.0 ± 3.59	97.0 ± 4.202; Ns	99.0 ± 3.929; Ns	94.5 ± 3.687; Ns	110.0 ± 3.325; (+13%, )*	116.0 ± 3.733; (+20%, )*	112.0 ± 5.529; (+16%, )*
LDL-Cholesterol; mg/dL	181.0 ± 8.56	207.0  ±  6.71; Ns	214.0 ± 12.47; (+18%, )*	260.0 ± 11.88; (+44%, )*	217.0 ± 8.91; (+20%, )*	233.0 ± 12.14; (+29%, )*	229.0 ± 15.32; (+27%, )*
HDL-Cholesterol; mg/dL	59.0 ± 2.9	48.5 ± 2.59; (−18%, )*	45.0 ± 2.01; (−24%, )*	42.9 ± 1.95; (−27%, )*	40.0 ± 1.69; (−32%, )	40.5 ± 1.89; (−31%, )*	39.0 ± 2.45; (−33%, )*
Lactate dehydrogenase; Units/L	428.0 ± 34.5	617.0 ± 42.12; (+44%, )*	409.7 ± 33.37; Ns	369.5 ± 28.43; NS	640.0 ± 95.64; (+50%, )	530.0 ± 54.77; Ns	508.0 ± 23.47; Ns
Creatine kinase MB; Units/L	411.0 ± 47.1	764.0 ± 51.22; (+86%, )*	703.0 ± 48.08; (+71%, )*	787.0 ± 52.13; (+91%, )*	822.0 ± 60.60; (+100%, )*	833.0 ± 53.45; (+103%, )	543.5 ± 54.59; NS
Homocysteine; mole homocysteine/L	11.78 ± 0.692	14.76 ± 1.108; (+25%, )*	9.5 ± 0.358; (−19%, )*	9.98 ± 0.395; Ns	11.84 ± 0.963; Ns	8.84 ± 0.227; (−25%, )*	10.6 ± 0.496; Ns

Values are expressed as Mean ± SEM.
NS: values are not significant statistically compared to control group where .
*Values are significant compared to control group where .